登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式(希尔记法):
C24H36N4O6S2
化学文摘社编号:
分子量:
540.70
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
罗咪酯肽, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 25 mg/mL, clear
storage temp.
−20°C
SMILES string
O=C(N/C(C(N[C@@H](C(C)C)C(O[C@@]1([H])CC2=O)=O)=O)=C\C)[C@@H](CSSCC/C=C/1)NC([C@H](N2)C(C)C)=O
InChI
1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1
InChI key
OHRURASPPZQGQM-GCCNXGTGSA-N
Gene Information
Biochem/physiol Actions
罗米地辛可促进细胞凋亡,同时阻碍神经胶质瘤模型中肿瘤的生长。
罗米地辛是HDAC1和HDAC2的一种非常有效的天然前药抑制剂,可被谷胱甘肽转化为活性形式。罗米地辛对HDAC1和HDAC2的IC50 值分别为36 nM和47 nM。它可杀死过表达Bcl-2和Bcl-XL的淋巴瘤细胞系,并已被批准用于治疗皮肤T细胞淋巴瘤(CTCL)和外周T细胞淋巴瘤,以及多种其他癌症。
罗米地辛是HDAC1和HDAC2的非常有效的天然前药抑制剂;抗肿瘤药。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Qin Xu et al.
American journal of physiology. Heart and circulatory physiology, 311(5), H1139-H1149 (2016-11-03)
Histone deacetylase (HDAC) inhibitors are small molecule anticancer therapeutics that exhibit limiting cardiotoxicities including QT interval prolongation and life-threatening cardiac arrhythmias. Because the molecular mechanisms for HDAC inhibitor-induced cardiotoxicity are poorly understood, we performed whole cell patch voltage-clamp experiments to
Florencia Cayrol et al.
Nature communications, 8, 14290-14290 (2017-01-31)
Peripheral T-cell lymphomas (PTCL) are aggressive diseases with poor response to chemotherapy and dismal survival. Identification of effective strategies to target PTCL biology represents an urgent need. Here we report that PTCL are sensitive to transcription-targeting drugs, and, in particular
Sina Jostes et al.
Journal of cellular and molecular medicine, 21(7), 1300-1314 (2016-12-28)
Type II testicular germ cell cancers (TGCT) are the most frequently diagnosed tumours in young men (20-40 years) and are classified as seminoma or non-seminoma. TGCTs are commonly treated by orchiectomy and chemo- or radiotherapy. However, a subset of metastatic
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML1175-1MG | 04061826274460 |